1.	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: TaCyDexVMP7, NCT00652041
2.	Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: 01-002-0601, NCT00205751
3.	Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 000080, 00-C-0080, NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085, NCT00004635
4.	Phase III Randomized Study of Interferon alfa-2b With or Without Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-2898, NCT00005966, E2898
5.	Phase III Randomized Study of Doxorubicin, Dexamethasone, and High-Dose Melphalan With or Without Thalidomide in Patients With Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CKTO-2001-02, HOVON-50MM, EU-20133, HOVON-CKVO-2001-02, NCT00028886
6.	Phase III Randomized Study of Radiotherapy With or Without Thalidomide in Patients With Multiple Brain Metastases Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: RTOG-BR-0118, RTOG-DEV-1006, NCT00033254
7.	Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000069274, E-E1A00, E1A00, NCT00033332
8.	Phase III Randomized Study of Tamoxifen Versus Thalidomide in Patients With Only a Biochemical Recurrence of Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer After First-Line Chemotherapy Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0198, NCT00041080
9.	Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 16 and over Sponsor: NCI, Other Protocol IDs: MY10, CAN-NCIC-MY10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, CELGENE-CAN-NCIC-MY10, CDR0000258158, NCIC-MY.10, NCT00049673
10.	Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000302440, LLCG-STUDY-12, EU-20207, ISRCTN16174527, NCT00061919
11.	A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: THAL-MM-003, NCT00057564
12.	Thalidomide + Dexamethasone vs. DOXIL (Doxorubicin HCl Liposome Injection) + Thalidomide + Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR004579, NCT00097981
13.	Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2005-01, NCT00111748
14.	Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 2004.00, NCI-2009-01543, FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
15.	Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MCC-13043, CZOL446E, NCT00215943
16.	Thalidomide to Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: NMSG #12, NFR 90000288, NCT00218855
17.	The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: Under 60 Sponsor: Other Protocol IDs: MM01, NCT00207805
18.	MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
19.	Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000530050, P30CA015083, MC0289, 421-03, MAYO-MC0289, MAYO-IRB-421-03, NCT00432458
20.	GEM05 for Patients With Multiple Myeloma More Than 65 Years Old Phase: Phase III Type: Treatment Status: Completed Age: 66 and over Sponsor: Other Protocol IDs: 2005-001111-21, NCT00443235
21.	Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: THA PH INT 2005 CL 001, NCT00452569
22.	GEM05 for Patients With Multiple Myeloma Under 65 Years Phase: Phase III Type: Treatment Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: 2005-001110-41, NCT00461747
23.	Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C05009, NCT00507416
24.	UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Other Protocol IDs: UARK 2006-66, NCT00572169
25.	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00522, U10CA021115, CDR0000583984, E1A06, ECOG-E1A06, NCT00602641